Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruboxistaurin - DermBiont

Next Previous
Drug Profile

Ruboxistaurin - DermBiont

Alternative Names: Arxxant; DBI-102; LY-333531; REC 3599; SM 030

Latest Information Update: 08 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer DermBiont; Eli Lilly and Company; Recursion Pharmaceuticals; Takeda
  • Class Amines; Eye disorder therapies; Heart failure therapies; Indoles; Maleimides; Skin disorder therapies; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Protein kinase C beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperpigmentation; Melanosis
  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; GM2 gangliosidoses; Heart failure

Most Recent Events

  • 08 Nov 2024 Phase-II clinical trials in Melanosis in El Salvador (Topical) (NCT06454747)
  • 24 Oct 2023 DermBiont plans a phase II meeting with the US FDA in the second half of 2024
  • 31 Dec 2022 Discontinued - Phase-I for GM2 gangliosidoses in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top